These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30962682)

  • 1. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
    Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
    Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical burden of illness among patients with severe eosinophilic COPD.
    Müllerová H; Meeraus WH; Galkin DV; Albers FC; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():741-755. PubMed ID: 31114180
    [No Abstract]   [Full Text] [Related]  

  • 3. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS; Pascoe KC; Siddall J; Small M; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2711-2723. PubMed ID: 31819403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong.
    Ko FWS; Xu X; Chau C; Navarro A; Hui DSC; Milea D
    Respir Med; 2024 Feb; 222():107516. PubMed ID: 38184091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
    Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
    Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
    Bogart M; Stanford RH; Laliberté F; Germain G; Wu JW; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():343-352. PubMed ID: 30863037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England.
    Sansbury LB; Wood RP; Anley GA; Nam Y; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2795-2808. PubMed ID: 34675504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
    Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
    COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.
    Vogelmeier CF; Kostikas K; Fang J; Tian H; Jones B; Morgan CL; Fogel R; Gutzwiller FS; Cao H
    Respir Res; 2019 Aug; 20(1):178. PubMed ID: 31391053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort.
    Trudo F; Kallenbach L; Vasey J; Chung Y; Wilk A; Slipski L; O'Brien D; Strange C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2625-2637. PubMed ID: 32063703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.
    Mathioudakis AG; Bikov A; Foden P; Lahousse L; Brusselle G; Singh D; Vestbo J
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32108044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.